Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · IEX Real-Time Price · USD
0.400
-0.007 (-1.82%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Unicycive Therapeutics Stock Forecast
UNCY's stock price has decreased by -68% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for UNCY stock have an average target of 5.63, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 1,307.50% from the current stock price of 0.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UNCY stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 2 | 2 | 2 | 2 | 1 |
Buy | 2 | 2 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4.5 | Strong Buy | Reiterates | $4.5 | +1,025.00% | Jul 10, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4.5 | Strong Buy | Reiterates | $4.5 | +1,025.00% | Jun 25, 2024 |
Benchmark | Benchmark | Buy Reiterates $3 | Buy | Reiterates | $3 | +650.00% | Jun 3, 2024 |
Benchmark | Benchmark | Buy Reiterates $3 | Buy | Reiterates | $3 | +650.00% | May 31, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4.5 | Strong Buy | Reiterates | $4.5 | +1,025.00% | May 29, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.57M
EPS This Year
-1.00
from -1.28
EPS Next Year
-0.25
from -1.00
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 123.4M | 522.5M | 1.2B | 404.1M |
Avg | n/a | 31.6M | 243.7M | 449.2M | 214.2M |
Low | n/a | 2.0M | 19.3M | 37.5M | 60.2M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 1,555.4% | 390.4% | -10.0% |
Avg | - | - | 672.0% | 84.3% | -52.3% |
Low | - | - | -38.8% | -84.6% | -86.6% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.50 | 0.71 | 5.11 | 10.55 | 2.60 |
Avg | -1.00 | -0.25 | 1.64 | 3.41 | 1.19 |
Low | -1.49 | -0.79 | -0.53 | -0.21 | 0.28 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | 542.6% | -23.6% |
Avg | - | - | - | 107.7% | -65.1% |
Low | - | - | - | - | -91.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.